TMO - Thermo Fisher Scientific Inc.
| Previous Close | 318.08 |
| Open | 318.68 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1200 |
| Day's Range | 318.14 - 322.17 |
| 52 Week Range | 208.34 - 322.17 |
| Volume | 973,728 |
| Avg. Volume | 1,338,601 |
| Market Cap | 128B |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | 35.92 |
| EPS (TTM) | 8.89 |
| Earnings Date | Jan 28, 2020 - Feb 3, 2020 |
| Forward Dividend & Yield | 0.76 (0.24%) |
| Ex-Dividend Date | 2019-12-16 |
| 1y Target Est | 321.13 |
- GuruFocus.com
MS Global Franchise Fund Buys 1, Sells 1 in 3rd Quarter
Fund invests in Thermo Fisher, exits Clorox position Continue reading...
- Zacks
Thermo Fisher (TMO) at a 52-Week High: What's Driving It?
Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.
- Zacks
Patterson Companies (PDCO) Q2 Earnings Surpass Estimates
Patterson Companies' (PDCO) Q2 results benefit from higher revenues, gross margin expansion and solid show by Dental segment.
- Zacks
What's in the Cards for Cantel Medical (CMD) in Q1 Earnings?
Better-than-expected performance at both Medical and Dental segments is likely to have driven Cantel Medical (CMD) in Q1 earnings.
- Zacks
Here's Why You Should Hold on to HealthEquity (HQY) for Now
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
- Zacks
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
- Zacks
Thermo Fisher Rides on New Product Suite and Global Growth
A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.
- Zacks
The Zacks Analyst Blog Highlights: Procter & Gamble, Thermo Fisher, PayPal, NextEra Energy and Enterprise Products
The Zacks Analyst Blog Highlights: Procter & Gamble, Thermo Fisher, PayPal, NextEra Energy and Enterprise Products
- Zacks
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.
- Insider Monkey
Hedge Funds Still Very Bullish On Thermo Fisher Scientific Inc. (TMO)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
- Zacks
Top Analyst Reports for Procter & Gamble, Thermo Fisher & PayPal
Top Analyst Reports for Procter & Gamble, Thermo Fisher & PayPal
- Zacks
Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates
Veeva (VEEV) gains from solid segmental contributions in fiscal third quarter, raises fiscal 2020 view.
- PR Newswire
Maggie Yuen Appointed Chief Financial Officer Of Penumbra
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the appointment of Maggie Yuen as CFO of Penumbra, effective December 2, 2019.
- Zacks
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.
- Zacks
Here's Why You Should Hold on to Pacific Biosciences Stock
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
- Simply Wall St.
Did Thermo Fisher Scientific Inc.'s (NYSE:TMO) Recent Earnings Growth Beat The Trend?
Investors with a long-term horizong may find it valuable to assess Thermo Fisher Scientific Inc.'s (NYSE:TMO) earnings...
- Insider Monkey
Here is The 14th Most Popular Stock Among 752 Hedge Funds
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 750 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of September […]
- Zacks
Thermo Fisher (TMO) Up 4.1% Since Last Earnings Report: Can It Continue?
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
What's in the Cards for Veeva Systems (VEEV) in Q3 Earnings?
Robust product portfolio and higher revenues are likely to have benefited Veeva Systems (VEEV) in third-quarter fiscal 2020 earnings.
- Zacks
Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.
- PR Newswire
Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500
NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO) will replace Celgene Corp. (NASD: CELG) in the S&P 100, and ServiceNow Inc. (NYSE: NOW) will replace Celgene in the S&P ...
- Zacks
Medtronic (MDT) Beats on Q2 Earnings, Ups FY20 EPS Guidance
Medtronic (MDT) demonstrates improved performances at CER, banking on growth in all major business segments and geographies.
- MarketWatch
ServiceNow stock up 4% on news it is joining the S&P 500
ServiceNow Inc. will replace Celgene Corp. in the S&P 500 index before the open on Thursday, S&P Global said late Monday. Bristol-Myers Squibb Co. is acquiring Celgene in a deal expected to close soon. Lab equipment maker Thermo Fisher Scientific Inc. will join the S&P 100, S&P Global said in the statement. ServiceNow, a cloud computing company based in Santa Clara, Calif., said earlier Monday that Gina Mastantuono will be its new chief financial officer effective Jan. 13. Shares were 4% higher in the extended session, after ending the regular trading day up 2.4%.
- Zacks
Canopy Growth (CGC) Q2 Earnings & Revenues Miss Estimates
Canopy Growth (CGC) reports mixed fiscal second-quarter results on strength in its core segments.
- Barrons.com
Dutch Diagnostics Group Qiagen Is Looking Like a Hot Acquisition And Shares Are Soaring
Shares of Dutch genetic testing company Qiagen shot higher on Monday, after the company confirmed it had entered into discussions to “explore potential strategic alternatives” after receiving ”several nonbinding indications of interest.”
